Evaluation of anti-ds DNA antibody measurement by using commercial kits for use in a clinical laboratory
Annals of Saudi Medicine. 1995; 15 (4): 327-32
em Inglês
| IMEMR
| ID: emr-36332
ABSTRACT
Three hundred and seventy-six consecutive antinuclear antibody-positive sera were tested for anti-ds DNA antibody by using three commercial kits which use 125 I recombinant DNA [radioimmunoassay], highly purified calf thymus DNA [enzyme linked immunosorbent assay] and Crithidia lucilliae [immunofluorescence assay] as substrates. All patients' sera, after reviewing medical records, were classified into three broad groups Group I [systemic lupus erythematosus], Group II [rheumatic diseases and rheumatoid arthritis], and Group III [nonspecific ANA antibody test positive]. A sensitivity, specificity, positive predictive test value and negative predictive test value for Group I against Group II-III [generally these two groups of sera should not show any anti-ds DNA antibody] combined showed for Crithidia lucilliae [IF assay] 58.8%, 93.6%, 82% and 82%, for 125 I recombinant DNA [RIA] assay, 75.8%, 94%, 86.2% and 88.7% and calf thymus highly purified DNA [ELISA] assay using positive cut-off value >100 U/mL, 97.5%, 35%, 42.9% and 24%. The 125 I recombinant DNA [RIA] assay based on the principle of the Farr technique, which is still considered to be the gold standard for anti-ds DNA antibody detection, showed the best specificity and sensitivity among all three methods tested in this study
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Kit de Reagentes para Diagnóstico
/
DNA Recombinante
/
Radioimunoensaio
/
Técnicas de Imunoadsorção
Idioma:
Inglês
Revista:
Ann. Saudi Med.
Ano de publicação:
1995
Similares
MEDLINE
...
LILACS
LIS